You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorpromazine
Accession NumberDB00477  (APRD00482)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem]
Structure
Thumb
Synonyms
3-(2-chloro-10H-Phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
3-(2-Chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Aminazine
Chlorderazin
Chloropromazine
Chlorpromados
Chlorpromazine
Chlorpromazinum
Clorpromazina
Contomin
CPZ
Largactil
N-(3-Dimethylaminopropyl)-3-chlorophenothiazine
Thorazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorprom Tab 100mgtablet111.6 mgoralIcn Canada Ltd.1962-12-311998-08-13Canada
Chlorprom Tab 25mgtablet27.9 mgoralIcn Canada Ltd.1974-12-311998-08-13Canada
Chlorprom Tab 50mgtablet55.8 mgoralIcn Canada Ltd.1962-12-311998-08-13Canada
Chlorpromanyl 20 Syrdrops22.2 mgoralTechnilab Pharma Inc.1983-12-312004-08-03Canada
Chlorpromanyl 40 Drops Syr 44.5mg/mlsyrup44.5 mgoralTechnilab Pharma Inc.1986-12-312006-07-28Canada
Chlorpromazine HCl Inj 25mg/ml USPliquid25 mgintramuscular; intravenousMylan Pharmaceuticals Ulc1994-12-312015-11-03Canada
Chlorpromazine HCl Inj 27.9mg/mlliquid27.9 mgintramuscular; intravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311996-09-10Canada
Chlorpromazine HCl Inj USPsolution25 mgintramuscular; intravenousAlveda Pharmaceuticals IncNot applicableNot applicableCanada
Chlorpromazine Hydrochloride Injectionliquid27.9 mgintramuscular; intravenousSandoz Canada Incorporated1988-12-31Not applicableCanada
Chlorpromazine Tab 25mgtablet27.9 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Chlorpromazine Tablets B.P. 100mgtablet100 mgoralClonmel Healthcare Limited1992-12-311996-09-09Canada
Chlorpromazine Tablets B.P. 25mgtablet25 mgoralClonmel Healthcare Limited1992-12-311996-09-09Canada
Chlorpromazine Tablets B.P. 50mgtablet50 mgoralClonmel Healthcare Limited1992-12-311996-09-09Canada
Largactil 100liquid100 mgoralSanofi Aventis Canada Inc1963-12-312006-07-28Canada
Largactil 25liquid25 mgoralSanofi Aventis Canada Inc1960-12-312006-07-28Canada
Largactil 50solution50 mgintramuscular; intravenousAventis Pharma Inc1952-12-312005-08-01Canada
Largactil Drops 40mg/mldrops40 mgoralSanofi Aventis Canada Inc1952-12-312007-01-30Canada
Largactil Sup 100mgsuppository100 mgrectalSanofi Aventis Canada Inc1952-12-312006-07-28Canada
Novo-chlorpromazine 200mgtablet223.2 mgoralNovopharm Limited1970-12-312005-08-10Canada
Novo-chlorpromazine Tab 10mgtablet11.16 mgoralNovopharm Limited1971-12-312005-08-10Canada
Teva-chlorpromazinetablet50.0 mgoralTeva Canada Limited1967-12-31Not applicableCanada
Teva-chlorpromazinetablet25.0 mgoralTeva Canada Limited1967-12-31Not applicableCanada
Teva-chlorpromazinetablet100 mgoralTeva Canada Limited1967-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Chlorpromazinetablet55.7 mgoralApotex Inc1976-12-312011-08-05Canada
Apo Chlorpromazinetablet111.4 mgoralApotex Inc1976-12-312011-08-05Canada
Apo Chlorpromazinetablet27.9 mgoralApotex Inc1976-12-312011-08-05Canada
Chlorpromazinetablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
Chlorpromazinetablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
Chlorpromazinetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1973-01-03Not applicableUs
Chlorpromazine Hydrochlorideinjection25 mg/mLintramuscularWest Ward Pharmaceutical Corp.1974-07-25Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralMylan Institutional Inc.1994-11-23Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralCardinal Health2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralClinical Solutions Wholesale2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralMylan Institutional Inc.1994-11-23Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralClinical Solutions Wholesale, Llc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralREMEDYREPACK INC.2010-12-16Not applicableUs
Chlorpromazine Hydrochloridetablet, film coated25 mg/1oralPhysicians Total Care, Inc.1973-01-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralTYA Pharmaceuticals1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralCardinal Health2011-04-01Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated10 mg/1oralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralMylan Institutional Inc.1994-11-28Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated200 mg/1oralTYA Pharmaceuticals2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated200 mg/1oralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralREMEDYREPACK INC.2013-02-21Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralClinical Solutions Wholesale2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2010-08-04Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralCardinal Health2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralContract Pharmacy Services Pa2010-02-25Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated200 mg/1oralMylan Institutional Inc.1994-11-28Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralClinical Solutions Wholesale, Llc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated200 mg/1oralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine Hydrochlorideinjection25 mg/mLintramuscularTYA Pharmaceuticals1974-07-25Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated10 mg/1oralUpsher Smith Laboratories, Inc.2011-08-08Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralREMEDYREPACK INC.2013-03-13Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralClinical Solutions Wholesale2011-08-03Not applicableUs
Chlorpromazine Hydrochlorideinjection25 mg/mLintramuscularWest Ward Pharmaceutical Corp.1974-07-25Not applicableUs
Chlorpromazine Hydrochloridetablet200 mg/1oralREMEDYREPACK INC.2011-08-16Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralCardinal Health2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralContract Pharmacy Services Pa2010-02-25Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralSandoz Inc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated10 mg/1oralMylan Institutional Inc.1994-11-23Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated200 mg/1oralClinical Solutions Wholesale, Llc1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralCarilion Materials Management2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated100 mg/1oralREMEDYREPACK INC.2010-12-16Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated200 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralTYA Pharmaceuticals1974-07-09Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralUpsher Smith Laboratories, Inc.2011-08-03Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated25 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Chlorpromazine Hydrochloridetablet, sugar coated200 mg/1oralClinical Solutions Wholesale2011-08-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ChlorpromanylTechnilab (Canada)
LargactilSpecia
ThorazineGlaxoSmithKline
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Chlorpromazine hydrochloride
69-09-0
Thumb
  • InChI Key: FBSMERQALIEGJT-UHFFFAOYSA-N
  • Monoisotopic Mass: 354.072424754
  • Average Mass: 355.325
DBSALT000026
Categories
UNIIU42B7VYA4P
CAS number50-53-3
WeightAverage: 318.864
Monoisotopic: 318.095747015
Chemical FormulaC17H19ClN2S
InChI KeyInChIKey=ZPEIMTDSQAKGNT-UHFFFAOYSA-N
InChI
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
IUPAC Name
[3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia, control nausea and vomiting, For relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.
PharmacodynamicsChlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
Mechanism of actionChlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use).
Related Articles
AbsorptionReadily absorbed from the GI tract. Bioavailability varies due to first-pass metabolism by the liver.
Volume of distribution
  • 20 L/kg
Protein binding> 90% to plasma proteins, primarily albumin
Metabolism

Extensively metabolized in the liver and kidneys. It is extensively metabolized by cytochrome P450 isozymes CYP2D6 (major pathway), CYP1A2 and CYP3A4. Approximately 10 to 12 major metabolite have been identified. Hydroxylation at positions 3 and 7 of the phenothiazine nucleus and the N-dimethylaminopropyl side chain undergoes demethylation and is also metabolized to an N-oxide. In urine, 20% of chlopromazine and its metabolites are excreted unconjugated in the urine as unchanged drug, demonomethylchlorpromazine, dedimethylchlorpromazine, their sulfoxide metabolites, and chlorpromazine-N-oxide. The remaining 80% consists of conjugated metabolites, principally O-glucuronides and small amounts of ethereal sulfates of the mono- and dihydroxy-derivatives of chlorpromazine and their sulfoxide metabolites. The major metabolites are the monoglucuronide of N-dedimethylchlorpromazine and 7-hydroxychlorpromazine. Approximately 37% of the administered dose of chlorpromazine is excreted in urine.

SubstrateEnzymesProduct
Chlorpromazine
hydroxychlorpromazineDetails
Chlorpromazine
Not Available
chlorpromazine-N-oxideDetails
Chlorpromazine
Not Available
dedimethylchlorpromazineDetails
Chlorpromazine
Not Available
demonomethylchlorpromazineDetails
Chlorpromazine
Not Available
N-dedimethylchlorpromazineDetails
Route of eliminationKidneys, ~ 37% excreted in urine
Half life~ 30 hours
ClearanceNot Available
ToxicityAgitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, restlessness
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9757
Blood Brain Barrier+0.9795
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.787
P-glycoprotein inhibitor IInhibitor0.7164
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.7557
CYP450 2C9 substrateNon-substrate0.7617
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6477
CYP450 1A2 substrateInhibitor0.9305
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.9422
CYP450 2C19 inhibitorInhibitor0.5512
CYP450 3A4 inhibitorNon-inhibitor0.9375
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6601
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9309
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3196 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9536
hERG inhibition (predictor II)Inhibitor0.787
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Actavis mid atlantic llc
  • Pharmaceutical assoc inc div beach products
  • Wockhardt eu operations (swiss) ag
  • Roxane laboratories inc
  • Sandoz inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Marsam pharmaceuticals llc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Alpharma us pharmaceuticals division
  • Abbott laboratories pharmaceutical products div
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lederle laboratories div american cyanamid co
  • Purepac pharmaceutical co
  • Private formulations inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • West ward pharmaceutical corp
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Tabletoral111.4 mg
Tabletoral55.7 mg
Tabletoral111.6 mg
Tabletoral27.9 mg
Tabletoral55.8 mg
Dropsoral22.2 mg
Syruporal44.5 mg
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Liquidintramuscular; intravenous25 mg
Solutionintramuscular; intravenous25 mg
Injectionintramuscular25 mg/mL
Tabletoral200 mg/1
Tabletoral50 mg/1
Tablet, sugar coatedoral10 mg/1
Tablet, sugar coatedoral100 mg/1
Tablet, sugar coatedoral200 mg/1
Tablet, sugar coatedoral25 mg/1
Tablet, sugar coatedoral50 mg/1
Liquidintramuscular; intravenous27.9 mg
Tabletoral25 mg
Tabletoral50 mg
Liquidoral100 mg
Liquidoral25 mg
Solutionintramuscular; intravenous50 mg
Dropsoral40 mg
Suppositoryrectal100 mg
Tabletoral223.2 mg
Tabletoral11.16 mg
Tabletoral100 mg
Tabletoral25.0 mg
Tabletoral50.0 mg
Prices
Unit descriptionCostUnit
Chlorpromazine 25 mg/ml amp8.04USD ml
ChlorproMAZINE HCl 200 mg tablet1.19USD tablet
Chlorpromazine 200 mg tablet1.05USD tablet
ChlorproMAZINE HCl 100 mg tablet0.84USD tablet
ChlorproMAZINE HCl 50 mg tablet0.73USD tablet
ChlorproMAZINE HCl 25 mg tablet0.55USD tablet
Chlorpromazine 100 mg tablet0.39USD tablet
ChlorproMAZINE HCl 10 mg tablet0.37USD tablet
Chlorpromazine 10 mg tablet0.32USD tablet
Chlorpromazine 50 mg tablet0.3USD tablet
Chlorpromazine 25 mg tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point177-178Charpentier, P.; U S . Patent 2,645,640; July 14, 1953; assigned to Societe des Usines Chimiques Rhone-Poulenc, France
boiling point200-205 °C at 8.00E-01 mm HgPhysProp
water solubility2.55 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.41AVDEEF,A (1995)
logS-5.01ADME Research, USCD
Caco2 permeability-4.7ADME Research, USCD
pKa9.3 (at 25 °C)HANSCH,C & LEO,AJ (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00417 mg/mLALOGPS
logP5.18ALOGPS
logP4.54ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.76 m3·mol-1ChemAxon
Polarizability35.1 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.36 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9231000000-ed14fee152701eacf689View in MoNA
References
Synthesis Reference

Charpentier, P.; U S . Patent 2,645,640; July 14, 1953; assigned to Societe des Usines Chimiques Rhone-Poulenc, France.

US2645640
General References
  1. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003 May 10;361(9369):1581-9. [PubMed:12747876 ]
External Links
ATC CodesN05AA01
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (75.4 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineChlorpromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineChlorpromazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Chlorpromazine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Chlorpromazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Chlorpromazine can be increased when it is combined with Abiraterone.
AcebutololChlorpromazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chlorpromazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Chlorpromazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Chlorpromazine.
adipiplonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorpromazine.
AgomelatineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Agomelatine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Chlorpromazine.
AlbendazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Chlorpromazine.
AlectinibThe serum concentration of Chlorpromazine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alfaxalone.
AlfentanilChlorpromazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe serum concentration of Chlorpromazine can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Chlorpromazine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chlorpromazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorpromazine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Chlorpromazine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Chlorpromazine.
AlphacetylmethadolChlorpromazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorpromazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorpromazine.
AlprenololChlorpromazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmantadineAmantadine may increase the QTc-prolonging activities of Chlorpromazine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chlorpromazine.
Aminohippuric acidThe serum concentration of Chlorpromazine can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Chlorpromazine.
AmiodaroneChlorpromazine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorpromazine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Chlorpromazine.
AmlodipineThe serum concentration of Chlorpromazine can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Chlorpromazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amperozide.
AmphetamineChlorpromazine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Chlorpromazine can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Chlorpromazine.
AmsacrineThe serum concentration of Chlorpromazine can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Chlorpromazine.
AnagrelideChlorpromazine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Chlorpromazine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Chlorpromazine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Chlorpromazine.
AprepitantThe serum concentration of Chlorpromazine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Chlorpromazine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Chlorpromazine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Chlorpromazine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Chlorpromazine.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Chlorpromazine.
ArotinololChlorpromazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideChlorpromazine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe serum concentration of Chlorpromazine can be increased when it is combined with Artemether.
ArtemetherChlorpromazine may increase the QTc-prolonging activities of Artemether.
ArtesunateThe serum concentration of Chlorpromazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Articaine.
AsenapineChlorpromazine may increase the QTc-prolonging activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorpromazine.
AstemizoleThe serum concentration of Chlorpromazine can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Chlorpromazine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Chlorpromazine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Chlorpromazine.
AtenololChlorpromazine may increase the hypotensive activities of Atenolol.
AtenololThe serum concentration of Chlorpromazine can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Chlorpromazine.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Chlorpromazine.
AtorvastatinThe serum concentration of Chlorpromazine can be increased when it is combined with Atorvastatin.
AtovaquoneThe serum concentration of Chlorpromazine can be increased when it is combined with Atovaquone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chlorpromazine.
AzaperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Azaperone.
AzelastineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Chlorpromazine can be increased when it is combined with Azelastine.
AzithromycinChlorpromazine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Chlorpromazine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital.
BedaquilineChlorpromazine may increase the QTc-prolonging activities of Bedaquiline.
BefunololChlorpromazine may increase the hypotensive activities of Befunolol.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Chlorpromazine.
BenzocaineThe serum concentration of Chlorpromazine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benzocaine.
BenzphetamineChlorpromazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Chlorpromazine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Chlorpromazine.
BepridilThe serum concentration of Chlorpromazine can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Chlorpromazine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chlorpromazine.
BetaxololChlorpromazine may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Chlorpromazine can be decreased when combined with Betaxolol.
BevantololChlorpromazine may increase the hypotensive activities of Bevantolol.
BexaroteneThe serum concentration of Chlorpromazine can be decreased when it is combined with Bexarotene.
BezitramideChlorpromazine may increase the hypotensive activities of Bezitramide.
BiperidenThe serum concentration of Chlorpromazine can be increased when it is combined with Biperiden.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololChlorpromazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Chlorpromazine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Chlorpromazine.
BopindololChlorpromazine may increase the hypotensive activities of Bopindolol.
BortezomibBortezomib may increase the QTc-prolonging activities of Chlorpromazine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Chlorpromazine.
BosentanThe serum concentration of Chlorpromazine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorpromazine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorpromazine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Chlorpromazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Chlorpromazine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
BrimonidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorpromazine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Chlorpromazine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Chlorpromazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Chlorpromazine.
BrotizolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Brotizolam.
BufuralolChlorpromazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Chlorpromazine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorpromazine.
BupranololChlorpromazine may increase the hypotensive activities of Bupranolol.
BuprenorphineChlorpromazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe serum concentration of Chlorpromazine can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Chlorpromazine.
BuserelinBuserelin may increase the QTc-prolonging activities of Chlorpromazine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorpromazine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Chlorpromazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorpromazine.
ButacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butethal.
ButorphanolChlorpromazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorpromazine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpromazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorpromazine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chlorpromazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chlorpromazine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Chlorpromazine.
CandesartanThe serum concentration of Chlorpromazine can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Chlorpromazine can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Chlorpromazine.
CarbamazepineThe serum concentration of Chlorpromazine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Chlorpromazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carbinoxamine.
CarfentanilChlorpromazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorpromazine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chlorpromazine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Chlorpromazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carisoprodol.
CarteololChlorpromazine may increase the hypotensive activities of Carteolol.
CarvedilolChlorpromazine may increase the hypotensive activities of Carvedilol.
CarvedilolThe serum concentration of Chlorpromazine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Chlorpromazine can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Chlorpromazine can be decreased when combined with Celecoxib.
CeliprololChlorpromazine may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Chlorpromazine.
CeritinibThe serum concentration of Chlorpromazine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chlorpromazine.
CetirizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Chlorpromazine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloral hydrate.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Chlorpromazine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorpromazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Chlorpromazine can be increased when it is combined with Chloroquine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Chlorpromazine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Chlorpromazine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Chlorpromazine.
ChlorphentermineChlorpromazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpropamideThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Chlorpromazine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorpromazine.
CholecalciferolThe metabolism of Chlorpromazine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Chlorpromazine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Chlorpromazine can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Chlorpromazine can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Chlorpromazine.
CimetidineThe serum concentration of Chlorpromazine can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Chlorpromazine.
CinacalcetThe metabolism of Chlorpromazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Chlorpromazine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Chlorpromazine.
CisaprideChlorpromazine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chlorpromazine.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Chlorpromazine.
CitalopramChlorpromazine may increase the QTc-prolonging activities of Citalopram.
ClarithromycinThe serum concentration of Chlorpromazine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Chlorpromazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Chlorpromazine.
ClidiniumThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chlorpromazine.
ClobazamThe metabolism of Chlorpromazine can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Chlorpromazine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chlorpromazine.
ClomipramineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chlorpromazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorpromazine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Chlorpromazine.
ClorazepateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clorazepate.
ClotrimazoleThe metabolism of Chlorpromazine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Chlorpromazine.
ClozapineThe metabolism of Chlorpromazine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Chlorpromazine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chlorpromazine.
CocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chlorpromazine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorpromazine.
ColchicineThe serum concentration of Chlorpromazine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Chlorpromazine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Chlorpromazine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorpromazine.
CrizotinibThe metabolism of Chlorpromazine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Chlorpromazine.
CyclizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorpromazine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.
CyclophosphamideThe serum concentration of Chlorpromazine can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Chlorpromazine.
CyclosporineThe metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Chlorpromazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Chlorpromazine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorpromazine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Chlorpromazine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Chlorpromazine.
DaclatasvirThe serum concentration of Chlorpromazine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chlorpromazine.
DantroleneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpromazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorpromazine.
DapoxetineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dapoxetine.
DapsoneThe serum concentration of Chlorpromazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Chlorpromazine.
DarunavirThe serum concentration of Chlorpromazine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Chlorpromazine.
DasatinibThe serum concentration of Chlorpromazine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Chlorpromazine can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Chlorpromazine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chlorpromazine.
DeferasiroxThe serum concentration of Chlorpromazine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Chlorpromazine.
DelavirdineThe metabolism of Chlorpromazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with deramciclane.
DesfluraneDesflurane may increase the QTc-prolonging activities of Chlorpromazine.
DesfluraneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Chlorpromazine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Chlorpromazine.
DesloratadineThe serum concentration of Chlorpromazine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorpromazine.
DetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Detomidine.
DexamethasoneThe serum concentration of Chlorpromazine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpromazine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Chlorpromazine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Chlorpromazine.
DextroamphetamineChlorpromazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Chlorpromazine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Chlorpromazine.
DextromoramideChlorpromazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorpromazine.
DextropropoxypheneChlorpromazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorpromazine.
DezocineChlorpromazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorpromazine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chlorpromazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorpromazine.
DiclofenacThe serum concentration of Chlorpromazine can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpromazine.
DifenoxinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chlorpromazine.
DigoxinThe serum concentration of Chlorpromazine can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Chlorpromazine.
DihydrocodeineChlorpromazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorpromazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorpromazine.
DihydroetorphineChlorpromazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorpromazine.
DihydromorphineChlorpromazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorpromazine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpromazine.
DiltiazemThe metabolism of Chlorpromazine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Chlorpromazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Chlorpromazine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Chlorpromazine.
DiphenoxylateChlorpromazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorpromazine.
DipyridamoleThe serum concentration of Chlorpromazine can be increased when it is combined with Dipyridamole.
DisopyramideChlorpromazine may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chlorpromazine.
DofetilideChlorpromazine may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Chlorpromazine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Chlorpromazine.
DomperidoneChlorpromazine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Chlorpromazine.
DopamineThe metabolism of Dopamine can be decreased when combined with Chlorpromazine.
DoramectinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Doramectin.
DoxazosinThe serum concentration of Chlorpromazine can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Chlorpromazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlorpromazine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Chlorpromazine.
DoxorubicinThe serum concentration of Chlorpromazine can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpromazine.
DoxycyclineThe serum concentration of Chlorpromazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
DoxylamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Doxylamine.
DPDPEChlorpromazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorpromazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
DronedaroneChlorpromazine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Chlorpromazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Chlorpromazine.
DrotebanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorpromazine.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Chlorpromazine.
DyclonineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorpromazine.
EfavirenzThe serum concentration of Chlorpromazine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efavirenz.
ElbasvirThe serum concentration of Chlorpromazine can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Chlorpromazine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chlorpromazine.
EliglustatChlorpromazine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Chlorpromazine can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Chlorpromazine can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Chlorpromazine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Chlorpromazine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorpromazine.
EntacaponeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Entacapone.
EnzalutamideThe serum concentration of Chlorpromazine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chlorpromazine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpromazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorpromazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorpromazine.
EribulinEribulin may increase the QTc-prolonging activities of Chlorpromazine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chlorpromazine.
ErythromycinThe metabolism of Chlorpromazine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Chlorpromazine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlorpromazine.
EscitalopramChlorpromazine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Chlorpromazine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Chlorpromazine.
EsmololChlorpromazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chlorpromazine.
EstramustineThe serum concentration of Chlorpromazine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Chlorpromazine can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Chlorpromazine.
EstroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Chlorpromazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorpromazine.
EthanolChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Chlorpromazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorpromazine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorpromazine.
EthosuximideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl loflazepate.
EthylmorphineChlorpromazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorpromazine.
EtidocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorpromazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etoperidone.
EtoposideThe serum concentration of Chlorpromazine can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Chlorpromazine.
EtorphineChlorpromazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorpromazine.
EtravirineThe serum concentration of Chlorpromazine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorpromazine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chlorpromazine.
EzogabineEzogabine may increase the QTc-prolonging activities of Chlorpromazine.
EzogabineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Chlorpromazine.
FelbamateFelbamate may increase the QTc-prolonging activities of Chlorpromazine.
FelbamateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Felbamate.
FelodipineThe serum concentration of Chlorpromazine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fenfluramine.
FentanylChlorpromazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorpromazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorpromazine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chlorpromazine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chlorpromazine.
FingolimodFingolimod may increase the QTc-prolonging activities of Chlorpromazine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Chlorpromazine.
FlecainideFlecainide may increase the QTc-prolonging activities of Chlorpromazine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Chlorpromazine.
FlibanserinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flibanserin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Chlorpromazine.
FludiazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Chlorpromazine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Chlorpromazine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorpromazine.
FluoxetineChlorpromazine may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolChlorpromazine may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Chlorpromazine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Chlorpromazine can be increased when it is combined with Fluphenazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Chlorpromazine.
FlurazepamThe serum concentration of Chlorpromazine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorpromazine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Chlorpromazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Chlorpromazine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Chlorpromazine.
FosamprenavirThe metabolism of Chlorpromazine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Chlorpromazine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Chlorpromazine.
FosphenytoinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Chlorpromazine.
Fusidic AcidThe serum concentration of Chlorpromazine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with gabapentin enacarbil.
Gadobenic acidChlorpromazine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Chlorpromazine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Chlorpromazine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chlorpromazine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chlorpromazine.
GemifloxacinChlorpromazine may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Chlorpromazine can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Glutethimide.
GlyburideThe serum concentration of Chlorpromazine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Chlorpromazine can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Chlorpromazine.
Gramicidin DThe serum concentration of Chlorpromazine can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Chlorpromazine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Chlorpromazine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chlorpromazine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorpromazine.
GuanfacineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Halazepam.
HalofantrineThe serum concentration of Chlorpromazine can be increased when it is combined with Halofantrine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Chlorpromazine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Chlorpromazine.
HalothaneThe metabolism of Halothane can be decreased when combined with Chlorpromazine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorpromazine.
HeroinChlorpromazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorpromazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Chlorpromazine.
HydrocodoneChlorpromazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorpromazine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorpromazine.
HydromorphoneChlorpromazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorpromazine.
Hydroxyamphetamine hydrobromideChlorpromazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Chlorpromazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Chlorpromazine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Chlorpromazine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Chlorpromazine.
IbutilideChlorpromazine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Chlorpromazine.
IdelalisibThe serum concentration of Chlorpromazine can be increased when it is combined with Idelalisib.
IloperidoneChlorpromazine may increase the QTc-prolonging activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Chlorpromazine.
ImatinibThe metabolism of Chlorpromazine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Chlorpromazine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorpromazine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Chlorpromazine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Chlorpromazine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Chlorpromazine.
IndalpineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Chlorpromazine.
IndenololChlorpromazine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Chlorpromazine can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Chlorpromazine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Chlorpromazine.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Chlorpromazine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chlorpromazine.
IsavuconazoniumThe metabolism of Chlorpromazine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorpromazine.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Chlorpromazine.
IsofluraneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Isoflurane.
IsoniazidThe metabolism of Chlorpromazine can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Chlorpromazine.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Chlorpromazine.
IvabradineIvabradine may increase the QTc-prolonging activities of Chlorpromazine.
IvacaftorThe serum concentration of Chlorpromazine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Chlorpromazine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Chlorpromazine.
KetamineThe serum concentration of Chlorpromazine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chlorpromazine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorpromazine.
KetobemidoneChlorpromazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorpromazine.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Chlorpromazine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Chlorpromazine.
LabetalolChlorpromazine may increase the hypotensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chlorpromazine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chlorpromazine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Chlorpromazine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chlorpromazine.
LapatinibLapatinib may increase the QTc-prolonging activities of Chlorpromazine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorpromazine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpromazine.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Chlorpromazine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Chlorpromazine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Chlorpromazine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chlorpromazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chlorpromazine.
LevobunololChlorpromazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Chlorpromazine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Chlorpromazine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Chlorpromazine.
Levomethadyl AcetateChlorpromazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorpromazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levomilnacipran.
LevorphanolChlorpromazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorpromazine.
LevothyroxineThe serum concentration of Chlorpromazine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Chlorpromazine can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Chlorpromazine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Chlorpromazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorpromazine.
LiothyronineThe serum concentration of Chlorpromazine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Chlorpromazine can be decreased when it is combined with Liotrix.
LisdexamfetamineChlorpromazine may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Chlorpromazine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Chlorpromazine.
LithiumLithium may increase the neurotoxic activities of Chlorpromazine.
LithiumThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lithium.
LofentanilChlorpromazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorpromazine.
LomitapideThe serum concentration of Chlorpromazine can be increased when it is combined with Lomitapide.
LomustineThe metabolism of Lomustine can be decreased when combined with Chlorpromazine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chlorpromazine.
LopinavirChlorpromazine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe serum concentration of Chlorpromazine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Chlorpromazine can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Chlorpromazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorpromazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorpromazine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Chlorpromazine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Chlorpromazine.
LovastatinThe metabolism of Chlorpromazine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorpromazine.
Lu AA21004The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Chlorpromazine can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Chlorpromazine can be increased when it is combined with Lumefantrine.
LumefantrineChlorpromazine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chlorpromazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorpromazine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Chlorpromazine.
MebendazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Medetomidine.
MefloquineThe serum concentration of Chlorpromazine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Chlorpromazine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Melperone.
MephentermineChlorpromazine may decrease the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Chlorpromazine.
MepivacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mepivacaine.
MeprobamateThe serum concentration of Chlorpromazine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Chlorpromazine.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Chlorpromazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorpromazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metaxalone.
MethadoneChlorpromazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorpromazine.
Methadyl AcetateChlorpromazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorpromazine.
MethamphetamineChlorpromazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorpromazine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chlorpromazine.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Chlorpromazine.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Chlorpromazine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Chlorpromazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorpromazine.
MethsuximideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpromazine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Chlorpromazine.
MetipranololChlorpromazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Chlorpromazine.
MetoprololChlorpromazine may increase the hypotensive activities of Metoprolol.
MetoprololThe serum concentration of Chlorpromazine can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Chlorpromazine.
MetyrosineChlorpromazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Chlorpromazine.
MexiletineThe metabolism of Chlorpromazine can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Chlorpromazine.
MibefradilThe serum concentration of Chlorpromazine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Chlorpromazine can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Chlorpromazine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Chlorpromazine.
MilnacipranThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Chlorpromazine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
MirabegronMirabegron may increase the QTc-prolonging activities of Chlorpromazine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Chlorpromazine.
MirtazapineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorpromazine.
MitomycinThe serum concentration of Chlorpromazine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Chlorpromazine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorpromazine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorpromazine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Chlorpromazine.
ModafinilThe serum concentration of Chlorpromazine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Chlorpromazine.
MolindoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Molindone.
MorphineChlorpromazine may increase the hypotensive activities of Morphine.
MorphineThe serum concentration of Chlorpromazine can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Chlorpromazine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpromazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
NabiloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nabilone.
NadololChlorpromazine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Chlorpromazine can be decreased when it is combined with Nafcillin.
NalbuphineChlorpromazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorpromazine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorpromazine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chlorpromazine.
NaltrexoneThe serum concentration of Chlorpromazine can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorpromazine.
NaringeninThe serum concentration of Chlorpromazine can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Chlorpromazine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Chlorpromazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorpromazine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Chlorpromazine.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Chlorpromazine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Chlorpromazine.
NeostigmineThe serum concentration of Chlorpromazine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Chlorpromazine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Chlorpromazine.
NevirapineThe metabolism of Chlorpromazine can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Chlorpromazine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Chlorpromazine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Chlorpromazine.
NicotineThe metabolism of Nicotine can be decreased when combined with Chlorpromazine.
NifedipineThe serum concentration of Chlorpromazine can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Chlorpromazine.
NilotinibChlorpromazine may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Chlorpromazine can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chlorpromazine.
NisoldipineThe serum concentration of Chlorpromazine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Chlorpromazine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrazepam.
NitrendipineThe serum concentration of Chlorpromazine can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Chlorpromazine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chlorpromazine.
NorethisteroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Chlorpromazine.
NormethadoneChlorpromazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorpromazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorpromazine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Chlorpromazine.
OctreotideOctreotide may increase the QTc-prolonging activities of Chlorpromazine.
OfloxacinChlorpromazine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olanzapine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Chlorpromazine.
OlaparibThe metabolism of Chlorpromazine can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Chlorpromazine.
OlopatadineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chlorpromazine.
OmeprazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Chlorpromazine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorpromazine.
OpiumChlorpromazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorpromazine.
OrphenadrineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Chlorpromazine.
OsanetantThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Osanetant.
OsimertinibThe serum concentration of Chlorpromazine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxazepam.
OxprenololChlorpromazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorpromazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxybuprocaine.
OxycodoneChlorpromazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorpromazine.
OxymorphoneChlorpromazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorpromazine.
OxytocinOxytocin may increase the QTc-prolonging activities of Chlorpromazine.
P-NitrophenolThe serum concentration of Chlorpromazine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Chlorpromazine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Chlorpromazine can be increased when it is combined with Palbociclib.
PaliperidoneChlorpromazine may increase the QTc-prolonging activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorpromazine.
Palmitic AcidThe serum concentration of Chlorpromazine can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Chlorpromazine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Chlorpromazine.
PanobinostatThe metabolism of Chlorpromazine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Chlorpromazine can be increased when it is combined with Pantoprazole.
ParaldehydeChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Chlorpromazine.
ParoxetineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Chlorpromazine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorpromazine.
PazopanibPazopanib may increase the QTc-prolonging activities of Chlorpromazine.
Peginterferon alfa-2bThe serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololChlorpromazine may increase the hypotensive activities of Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Chlorpromazine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Chlorpromazine.
PentazocineChlorpromazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorpromazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorpromazine.
PerampanelThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perampanel.
PerflutrenChlorpromazine may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Chlorpromazine.
PerindoprilThe serum concentration of Chlorpromazine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perospirone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Chlorpromazine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorpromazine.
PethidineChlorpromazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorpromazine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Chlorpromazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorpromazine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Chlorpromazine.
PhenobarbitalThe serum concentration of Chlorpromazine can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Chlorpromazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Phenoxyethanol.
PhentermineChlorpromazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chlorpromazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Chlorpromazine.
PimozideChlorpromazine may increase the QTc-prolonging activities of Pimozide.
PimozideThe serum concentration of Chlorpromazine can be increased when it is combined with Pimozide.
PindololChlorpromazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Chlorpromazine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Chlorpromazine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Chlorpromazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chlorpromazine.
PizotifenThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Chlorpromazine can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpromazine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chlorpromazine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chlorpromazine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Chlorpromazine.
PractololChlorpromazine may increase the hypotensive activities of Practolol.
PramipexoleChlorpromazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chlorpromazine.
PrazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazepam.
PrazosinThe serum concentration of Chlorpromazine can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chlorpromazine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chlorpromazine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorpromazine.
PrilocaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prilocaine.
PrimaquineThe serum concentration of Chlorpromazine can be increased when it is combined with Primaquine.
PrimaquineChlorpromazine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Primidone.
ProbenecidThe serum concentration of Chlorpromazine can be increased when it is combined with Probenecid.
ProcainamideChlorpromazine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorpromazine.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Chlorpromazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorpromazine.
ProgesteroneThe serum concentration of Chlorpromazine can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Chlorpromazine.
ProguanilThe serum concentration of Chlorpromazine can be increased when it is combined with Proguanil.
PromazineThe metabolism of Chlorpromazine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorpromazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Chlorpromazine.
PropafenoneThe serum concentration of Chlorpromazine can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Chlorpromazine.
ProparacaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Proparacaine.
PropofolPropofol may increase the QTc-prolonging activities of Chlorpromazine.
PropofolThe metabolism of Propofol can be decreased when combined with Chlorpromazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Propoxycaine.
PropranololChlorpromazine may increase the hypotensive activities of Propranolol.
PropranololThe serum concentration of Chlorpromazine can be increased when it is combined with Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorpromazine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Chlorpromazine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorpromazine.
PSD502The risk or severity of adverse effects can be increased when Chlorpromazine is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Chlorpromazine.
PyrimethamineThe serum concentration of Chlorpromazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quazepam.
QuercetinThe serum concentration of Chlorpromazine can be increased when it is combined with Quercetin.
QuetiapineChlorpromazine may increase the QTc-prolonging activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorpromazine.
QuinacrineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorpromazine.
QuinidineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinidine.
QuinidineChlorpromazine may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinine.
QuinineChlorpromazine may increase the QTc-prolonging activities of Quinine.
RadicicolThe serum concentration of Chlorpromazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ramelteon.
RanitidineThe serum concentration of Chlorpromazine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorpromazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorpromazine.
ReboxetineThe serum concentration of Chlorpromazine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Chlorpromazine can be increased when it is combined with Regorafenib.
RemifentanilChlorpromazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorpromazine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Chlorpromazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorpromazine.
repinotanThe metabolism of repinotan can be decreased when combined with Chlorpromazine.
ReserpineThe serum concentration of Chlorpromazine can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Chlorpromazine.
RifabutinThe metabolism of Chlorpromazine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Chlorpromazine can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Chlorpromazine.
RifapentineThe metabolism of Chlorpromazine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorpromazine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Chlorpromazine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Chlorpromazine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Chlorpromazine.
RitonavirRitonavir may increase the QTc-prolonging activities of Chlorpromazine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Chlorpromazine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpromazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorpromazine.
RolapitantThe serum concentration of Chlorpromazine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chlorpromazine.
RomifidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Romifidine.
RopiniroleChlorpromazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Chlorpromazine can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Chlorpromazine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorpromazine.
RotigotineChlorpromazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorpromazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Chlorpromazine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Chlorpromazine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Chlorpromazine.
SaquinavirThe serum concentration of Chlorpromazine can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Chlorpromazine.
ScopolamineThe serum concentration of Chlorpromazine can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorpromazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorpromazine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chlorpromazine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Chlorpromazine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Chlorpromazine.
SertralineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Chlorpromazine.
SevofluraneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sevoflurane.
SildenafilThe metabolism of Chlorpromazine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorpromazine.
SiltuximabThe serum concentration of Chlorpromazine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Chlorpromazine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Chlorpromazine can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Chlorpromazine.
SinefunginThe serum concentration of Chlorpromazine can be increased when it is combined with Sinefungin.
SirolimusThe serum concentration of Chlorpromazine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Chlorpromazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chlorpromazine.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Chlorpromazine.
SorafenibSorafenib may increase the QTc-prolonging activities of Chlorpromazine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Chlorpromazine.
SotalolChlorpromazine may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorpromazine.
SparteineThe metabolism of Sparteine can be decreased when combined with Chlorpromazine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chlorpromazine.
SpironolactoneThe serum concentration of Chlorpromazine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Chlorpromazine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Chlorpromazine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Stiripentol.
StreptozocinThe serum concentration of Chlorpromazine can be decreased when it is combined with Streptozocin.
SufentanilChlorpromazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorpromazine.
SulfadoxineThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfadoxine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Chlorpromazine.
SulfametopyrazineThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfametopyrazine.
SulfinpyrazoneThe serum concentration of Chlorpromazine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleChlorpromazine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Chlorpromazine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Chlorpromazine.
SunitinibSunitinib may increase the QTc-prolonging activities of Chlorpromazine.
SuvorexantThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Suvorexant.
TacrineThe serum concentration of Chlorpromazine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Chlorpromazine can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Chlorpromazine.
tafenoquineThe serum concentration of Chlorpromazine can be increased when it is combined with tafenoquine.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Chlorpromazine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Chlorpromazine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Chlorpromazine.
TapentadolChlorpromazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorpromazine.
TasimelteonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorpromazine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chlorpromazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorpromazine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Chlorpromazine.
TelaprevirThe metabolism of Chlorpromazine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Chlorpromazine.
TelavancinChlorpromazine may increase the QTc-prolonging activities of Telavancin.
TelithromycinChlorpromazine may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe serum concentration of Chlorpromazine can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorpromazine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpromazine.
TenofovirThe metabolism of Chlorpromazine can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Chlorpromazine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Chlorpromazine can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Chlorpromazine.
TerfenadineThe serum concentration of Chlorpromazine can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Chlorpromazine.
TeriflunomideThe serum concentration of Chlorpromazine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Chlorpromazine can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Chlorpromazine.
TestosteroneThe serum concentration of Chlorpromazine can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorpromazine.
TetrabenazineChlorpromazine may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetrodotoxin.
ThalidomideChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorpromazine.
TheophyllineThe metabolism of Chlorpromazine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Chlorpromazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorpromazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Chlorpromazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpromazine.
TiclopidineThe metabolism of Chlorpromazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiletamine.
TimololChlorpromazine may increase the hypotensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Chlorpromazine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Chlorpromazine.
TizanidineTizanidine may increase the QTc-prolonging activities of Chlorpromazine.
TizanidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tizanidine.
TocilizumabThe serum concentration of Chlorpromazine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Chlorpromazine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Chlorpromazine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chlorpromazine.
TopiramateThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorpromazine.
ToremifeneChlorpromazine may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Chlorpromazine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chlorpromazine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorpromazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorpromazine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chlorpromazine.
TrazodoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Chlorpromazine.
TriazolamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triazolam.
TrifluoperazineThe serum concentration of Chlorpromazine can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triflupromazine.
TrimethoprimThe serum concentration of Chlorpromazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorpromazine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Chlorpromazine.
TriprolidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Chlorpromazine.
TroleandomycinThe serum concentration of Chlorpromazine can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chlorpromazine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chlorpromazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chlorpromazine.
VandetanibChlorpromazine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Chlorpromazine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chlorpromazine.
VemurafenibThe serum concentration of Chlorpromazine can be increased when it is combined with Vemurafenib.
VemurafenibChlorpromazine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Chlorpromazine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Chlorpromazine.
VerapamilThe metabolism of Chlorpromazine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Chlorpromazine.
VigabatrinThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Chlorpromazine.
VilazodoneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vilazodone.
VinblastineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Chlorpromazine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorpromazine.
VincristineThe serum concentration of Chlorpromazine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Chlorpromazine can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Chlorpromazine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chlorpromazine.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Chlorpromazine.
VorinostatVorinostat may increase the QTc-prolonging activities of Chlorpromazine.
VortioxetineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Chlorpromazine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Chlorpromazine.
ZaleplonThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chlorpromazine.
ZimelidineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zimelidine.
ZimelidineThe serum concentration of Chlorpromazine can be increased when it is combined with Zimelidine.
ZiprasidoneChlorpromazine may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Chlorpromazine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorpromazine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Chlorpromazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Chlorpromazine.
ZonisamideThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zotepine.
ZuclopenthixolChlorpromazine may increase the QTc-prolonging activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorpromazine.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263 ]
  4. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]
  7. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
  8. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl). 1995 Aug;120(3):365-8. [PubMed:8524985 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438 ]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cosi C, Koek W: Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol. 2001 Dec 14;433(1):55-62. [PubMed:11755134 ]
  2. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ: Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. [PubMed:9760039 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
  2. Church MK, Young KD: The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol. 1983 Apr;78(4):671-9. [PubMed:6189542 ]
  3. Johnson HG, Miller MD: Inhibition of histamine release and ionophore-induced calcium flux in rat mast cells by lidocaine and chlorpromazine. Agents Actions. 1979 Aug;9(3):239-43. [PubMed:91313 ]
  4. Palmer GC, Wagner HR, Palmer SJ, Manian AA: Histamine-, norepinephrine-, and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine derivatives and butaclamol. Arch Int Pharmacodyn Ther. 1978 Jun;233(2):314-25. [PubMed:687395 ]
  5. Ruffolo RR, Patil PN: Kinetics of blockade of different receptors by chlorpromazine in rabbit stomach strips. Eur J Pharmacol. 1978 Mar 15;48(2):151-7. [PubMed:25190 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wu K, Kathofer S, Katus HA, Schoels W, Kiehn J, Karle CA: The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol. 2003 Jun;139(3):567-74. [PubMed:12788816 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993 Aug;6(4):602-8. [PubMed:8104554 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl). 1995 Aug;120(3):365-8. [PubMed:8524985 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg. 1993 Aug;6(4):602-8. [PubMed:8104554 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 2AP28223 Details
5-hydroxytryptamine receptor 2BP41595 Details
5-hydroxytryptamine receptor 2CP28335 Details
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA: Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70. [PubMed:6135146 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Bylund DB, Ray-Prenger C, Murphy TJ: Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther. 1988 May;245(2):600-7. [PubMed:2835476 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl). 2005 Apr;178(4):451-60. Epub 2004 Oct 13. [PubMed:15765260 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl). 2005 Apr;178(4):451-60. Epub 2004 Oct 13. [PubMed:15765260 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sphingomyelin phosphodiesterase activity
Specific Function:
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity.
Gene Name:
SMPD1
Uniprot ID:
P17405
Molecular Weight:
69751.3 Da
References
  1. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M, Satoyoshi E: Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem. 1985 Dec;98(6):1669-79. [PubMed:2419314 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Marshak DR, Lukas TJ, Watterson DM: Drug-protein interactions: binding of chlorpromazine to calmodulin, calmodulin fragments, and related calcium binding proteins. Biochemistry. 1985 Jan 1;24(1):144-50. [PubMed:2986673 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Components:
NameUniProt IDDetails
Alpha-1-acid glycoprotein 1P02763 Details
Alpha-1-acid glycoprotein 2P19652 Details
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. [PubMed:7908055 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF: Discovery of a novel member of the histamine receptor family. Mol Pharmacol. 2001 Mar;59(3):427-33. [PubMed:11179435 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  3. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K: Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000;67(2):175-84. [PubMed:10901285 ]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K: Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci. 2000;67(2):175-84. [PubMed:10901285 ]
  2. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Nasello AG, Gidali D, Felicio LF: A comparative study of the anticholinesterase activity of several antipsychotic agents. Pharmacol Biochem Behav. 2003 Jul;75(4):895-901. [PubMed:12957233 ]
  2. Muraoka S, Miura T: Inactivation of cholinesterase induced by chlorpromazine cation radicals. Pharmacol Toxicol. 2003 Feb;92(2):100-4. [PubMed:12747580 ]
  3. Spinedi A, Pacini L, Limatola C, Luly P, Farias RN: A study of human erythrocyte acetylcholinesterase inhibition by chlorpromazine. Biochem J. 1991 Sep 1;278 ( Pt 2):461-3. [PubMed:1654884 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214 ]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920 ]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23